- ABVC BioPharma Inc ABVC shares gained during the market trading session on continued momentum from yesterday's dietary supplement distribution deal and after a favorable report from Zacks Small-Cap Research.
- Yesterday, ABVC Biopharma announced that BioKey would produce dietary supplements derived from the maitake mushroom in tablet and liquid forms.
- In addition, BioKey has entered into a three-year distribution agreement with Define Biotech Co Ltd, Taiwan-based pharmaceutical marketing.
- Zacks Small-Cap Research analyst M. Marin highlighted the company's two lead candidates, ABV-1505 and Vitargus (ABV-1701).
- ABV-1505 is in Phase 2 for adult attention-deficit/hyperactivity disorder. Zacks values the ABVC stock at $9.50.
- In 2022, ABVC is planning to begin a self-funded pivotal trial for Vitargus for retinal detachment vitreous hemorrhage.
- Price Action: ABVC shares gained almost 20% at $4.08 before pulling back at $3.53, +6.68% during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: NewsPenny StocksHealth CareContractsAnalyst RatingsMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
